Novel Carbonyl Analogues of Tamoxifen: Design, Synthesis.
Tamoxifen which works as a PKC antagonist is an anticancer and antiestrogen drug. Tamoxifen is a suitable drug for evaluating the therapeutic potential of PKC antagonist in the treatment of L-DOPA. The purpose of this study is to prove that the side effects of L-DOPA could be reduced with the use of tamoxifen.Tamoxifen is an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen.The anticancer drug tamoxifen binds to the estrogen receptor. Tamoxifen inhibits the growth of breast tissue, but promotes growth of uterine tissues, thus reducing the risk of breast cancer, but potentially increasing the risk of uterine cancer. Explain how the same chemical messenger could have opposite effects in two different tissues.
Search results for tamoxifen at Sigma-Aldrich. Summary: This gene belongs to the brain expressed X-linked gene family. The encoded protein interacts with the transcription factor LIM domain only 2 in a DNA-binding complex that recognizes the E-box element and promotes transcription.This is not an example of the work produced by our Essay Writing Service. You can view. Drugs are aimed either to change the ER signaling pathways or prevent estrogen synthesis.7 Tamoxifen and 3rd generation Aromatase Inhibitors (AI) have been used for advance breast cancer with the former being effective in premenopausal, perimenopausal and.
Tamoxifen is a SERM, a PKC inhibitor and an anti-angiogenetic factor. Tamoxifen i is metabolized to 4-hydroxytamoxifen (4-OHT) and endoxifen by CYP2D6 and CYP3A4. In breast cancer, tamoxifen activity is dependent upon PAX2. Blocks estradiol-stimulated VEGF production in breast tumor cells.
